You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
26 June 2026 - Australian-based clinical-stage biopharmaceutical company Racura Oncology Limited (ASX:RAC) announced on Thursday that the first patient has been dosed with RC220 in HARNESS-1, a Phase 1a/b clinical trial evaluating RC220 in combinatio...
26 June 2026 - Late-clinical stage biotechnology company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) on Thursday reported positive biomarker findings from its Phase 2 randomised, double-blind, placebo-controlled proof-of-concept RoAD study (NST-AD-001)...
26 June 2026 - LyGenesis, Inc., a US-based, clinical-stage biotechnology company developing cell therapies for organ regeneration, announced on Thursday that it has received a research award from Breakthrough T1D, a New York-based global type 1 diabe...
25 June 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Thursday that the US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizuma...
25 June 2026 - Biosidus, an Argentina-based biotechnology company, announced on Wednesday the signing of a licensing and supply agreement with Mubadala Bio, the life sciences platform of Mubadala Investment Company, to introduce a portfolio of biolog...
25 June 2026 - Clinical-stage biopharmaceutical company Vascarta Inc announced on Wednesday the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor; topical curcumin gel) for the treatment of sickle...
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
25 June 2026 - Cirius Therapeutics Inc, a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, announced on Wednesday that enrolment and dosing has begun in a Phase 2 clinica...